<DOC>
	<DOCNO>NCT01093235</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , fluorouracil , epirubicin hydrochloride , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether give combination chemotherapy together without bevacizumab effective treating patient nonmetastatic breast cancer . PURPOSE : This randomized phase III trial study well give combination chemotherapy work compare give combination chemotherapy together bevacizumab treat patient nonmetastatic breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Bevacizumab Treating Patients With Nonmetastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare efficacy neoadjuvant therapy comprise docetaxel , fluorouracil , epirubicin hydrochloride , cyclophosphamide versus without bevacizumab patient HER2-negative nonmetastatic breast cancer . Secondary - To assess quality life female patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord age ( ≤ 50 year old v &gt; 50 year old ) , estrogen receptor status ( negative [ Allred score 0-2 ] v weakly positive [ Allred score 3-5 ] v strongly positive [ Allred score 6-8 ] ) , total tumor size* ( ≤ 50 mm v &gt; 50 mm ) , clinical involvement axillary node ( yes v ) , inflammatory/locally advanced disease ( T4 ) ( yes v ) . Patients randomize 1 2 treatment arm . NOTE : *In case multifocal disease one breast , bilateral disease , size use stratification sum single large diameter measurable tumor . - Arm I : Patients receive docetaxel IV day 1 ; treatment repeat every 3 week 3 course . Patients receive fluorouracil IV , epirubicin hydrochloride IV , cyclophosphamide IV day 1 ( FEC ) . Treatment fluorouracil , epirubicin hydrochloride , cyclophosphamide repeat every 3 week 3 course . - Arm II : Patients receive bevacizumab IV 30 90 minute docetaxel IV day 1 ; treatment repeat every 3 week 3 course . Patients receive FEC arm I . Treatment FEC repeat every 3 week 3 course . Patients also receive bevacizumab IV 30 90 minute docetaxel IV day 1 FEC course 1 . Within 3-6 week completion last dose study therapy , patient arm undergo surgery . Within 4-8 week surgery , patient undergo radiotherapy accord standard protocol . Women complete quality-of-life questionnaire ( FACT-B EuroQoL ) baseline completion study treatment . After completion study treatment , patient follow every 6 month 2 year annually 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Postoperative Complications</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer HER2negative disease IHC 0/1 OR IHC 2+ FISH negative Must meet 1 follow criterion : Unifocal tumor meeting 1 follow criterion : T2 T3 tumor ( radiological size &gt; 20 mm ) T4 tumor size direct extension chest wall skin Inflammatory carcinoma tumor size Multifocal tumor meeting follow criterion : The sum tumor ' maximum diameter must ≥ 20 mm ( total radiological tumor size ≥ 20 mm ) Other locally advanced disease meet 1 follow criterion : Any T stage involvement large fix axillary lymph node ( radiological diameter &gt; 20 mm clinical N2 ) primary breast tumor diameter Any T stage involvement large fix axillary lymph node ( radiological diameter &gt; 20 mm clinical N2 ) , without primary breast tumor identify presence breast cancer lymph node must histopathologically confirm lymph node biopsy ( trucut whole lymph node ) Embedded paraffin tumor block available prechemotherapy biopsy surgical specimen Bilateral disease allow No evidence metastatic disease No prior breast cancer except ductal carcinoma situ breast surgically cure &gt; 10 year ago Any hormone receptor status PATIENT CHARACTERISTICS : ECOG performance status 02 WBC &gt; 3 x 10^9/L Hemoglobin &gt; 10 g/dL Platelet count &gt; 100 x 10^9/L AST/ALT ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN Bilirubin normal Isolated elevation bilirubin ≤ 3 time ULN presumptive diagnosis Gilbert syndrome allow AST/ALT alkaline phosphatase within normal limit Creatinine ≤ 1.5 time ULN PT PTT/aPTT ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception Must fit receive chemotherapy trial , opinion responsible clinician , indicate follow criterion : No clinically significant cardiac abnormalities No myocardial infarction within past 6 month LVEF normal ( least 50 % ) MUGA scan echocardiogram No prior ischemic heart disease , cerebrovascular disease , peripheral vascular disease , arterial venous thromboembolic disease , cardiac failure , inflammatory bowel disease , gastroduodenal ulcer , symptomatic diverticulitis , bleed diathesis No uncontrolled hypertension ( systolic BP &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg ) without antihypertensive medication Patients initial blood pressure elevation eligible provided initiation adjustment antihypertensive medication lower pressure meet entry criterion No previous malignancy except basal cell carcinoma , carcinoma situ cervix , ductal carcinoma situ breast treat surgery diseasefree 10 year No concurrent medical psychiatric problem might prevent completion treatment followup No presence active uncontrolled infection No history nephritic nephrotic syndrome No traumatic injury within past 28 day No evidence disease , opinion investigator , place patient high risk treatmentrelated complication No nonhealing wound , peptic ulcer , bone fracture PRIOR CONCURRENT THERAPY : No prior neoadjuvant endocrine therapy No prior chemotherapy radiotherapy No major surgical procedure within past 28 day No concurrent full therapeutic dose anticoagulant aspirin &gt; 325 mg/day , clopidogrel &gt; 75 mg/day , corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>cardiac toxicity</keyword>
	<keyword>perioperative/postoperative complication</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>